Indian agency objects to Mylan vaccine plant deal

An Indian agency has objected to Mylan's ($MYL) planned takeover of Agila Specialties because it would transfer another vaccine plant to a foreign owner. Indian officials fear the sale of the vaccine and oncology plants will limit the country's ability to supply affordable medicines to citizens. News

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.